tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Amedisys Acquisition Faces Intense Regulatory Review

Amedisys Acquisition Faces Intense Regulatory Review

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Amedisys Inc (AMED) just unveiled an announcement.

The Oregon Health Authority has initiated a detailed review of UnitedHealth Group’s proposed acquisition of Amedisys, with the process expected to take up to 180 days from December 4, 2023. Approval from the OHA is a critical requirement for the transaction to proceed, highlighting the significant regulatory scrutiny such healthcare market deals undergo. This development is a key consideration for stakeholders and investors watching the evolving landscape of the healthcare industry.

See more insights into AMED stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1